Jaguar Health (JAGX) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Conference overview

• Over 600 companies presented across sectors including life sciences, cryptocurrency, and blockchain.

• Focus on corporate finance, strategic advisory, and value creation for public and private companies.

Product and clinical development updates

• Mytesi, an FDA-approved, plant-based drug for HIV-related diarrhea, is the only oral drug approved under botanical guidance, offering long-term exclusivity.

• Net revenue for Mytesi grew 16% in Q2 2024 to $2.7 million, with a U.S. market potential of $20–30 million.

• Crofelemer is conditionally approved for chemotherapy-induced diarrhea in dogs; human use is under further development.

• A pivotal phase III trial for cancer therapy-related diarrhea did not meet its primary endpoint but showed positive responder analysis in breast and lung cancer subpopulations.

• Ongoing analysis of extended trial data and preparation for FDA discussions to advance Crofelemer for these subpopulations.

Pipeline and rare disease focus

• Crofelemer holds orphan drug designation for short bowel syndrome and MVID, targeting catastrophic intestinal failure conditions.

• Five clinical efforts are ongoing, including three investigator-initiated studies and two global phase 2 trials enrolling by year-end.

• Early patient access and revenue opportunities are being pursued in Europe, leveraging a specialized team in Italy.

• The intestinal failure market is estimated at $5–12 billion, with Crofelemer offered in a distinct, highly concentrated liquid formulation.